Tobacco & Nicotine Products
( Epidemiology and Biostatistics Faculty)
Das, Babita (UMD SPH Behavioral and Community Health), Cruz-Cano, Raul (UMD SPH Epidemiology and Biostatistics), Kim, Hyoshin (Battelle Seattle Research Center), Brinkman, Marielle (Battelle Seattle Research Center), Clark, Pamela (UMD SPH Behavioral and Community Health)
The last few decades have witnessed a substantial increase in the use of smokeless tobacco (ST) products such as snuff, chewing tobacco, snus, and dissolvable nicotine products. The characterization of new ST products is vital to understanding their rise in popularity and the consequences of their use. The current study administered a series of cross-over trials to rapidly characterize the abuse liability and likelihood of adoption of a variety of ST products. In Trial 1, reported here, 30 smokeless tobacco users used Skoal tobacco, Camel snus, Ariva dissolvables, Verve nicotine discs, or Nicorette lozenges (control product) on each of five separate laboratory visits. Differences between products in self-reported liking, change in craving, and change in withdrawal were measured. Repeated measures mixed model analysis revealed significant differences between products in the aversion (p<.001), reduced craving (p=.002), and satisfaction factors (p=.014), plus overall reinforcement (p<.001), as measured by the Cigarette Evaluation Scale modified for Smokeless Tobacco. Significant differences were also found between products in ratings of liking (p=.014), satisfaction (p=.032), nicotine content (p<.001), and strength of the tobacco (p<.001) as measured by the Duke Sensory Questionnaire modified for Smokeless Tobacco. No significant differences were found between products in overall relief of craving or withdrawal. Skoal tobacco consistently produced the highest ratings of liking and reduction in craving across measures. These preliminary findings reveal diversity in the abuse liability and likelihood of adoption across ST product types. Relationships between the characterization (nicotine content) and ratings of sensations and relief of craving from these products, and between neurocognitive boost measures (ERP) and ratings of relief from craving and withdrawal, are currently being examined.